Abstract P2-15-14: Triple negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA studyGiorgio Mustacchi, Paolo Marchetti, Ornella Garrone et al.|Cancer Research|2020Cited by 0
Abstract P5-07-10: Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA studyMarina Elena Cazzaniga, Sabino De Placido, Alessia D’Alonzo et al.|Cancer Research|2020Cited by 0
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Change of Molecular Subtype at Re-Biopsy. Insights from the GIM-13 - AMBRA StudyMarina Elena Cazzaniga, Giorgio Mustacchi, P. Pronzato et al.|Preprints.org|2025Cited by 0
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA StudyMarina Elena Cazzaniga, Giorgio Mustacchi, P. Pronzato et al.|Cancers|2025Cited by 0